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Abstract 
Individuals of African ancestry in the US and Europe are at increased risk of developing 
schizophrenia and have poorer clinical outcomes. The antipsychotic clozapine, the only 
licensed medication for treatment-resistant schizophrenia, is under-prescribed and has 
high rates of discontinuation in individuals of African ancestry, due in part to increased 
rates of neutropenia. The genetic basis of lower neutrophil levels in those of African 
ancestry has not previously been investigated in the context of clozapine treatment. We 
sought to identify risk alleles in the first genome-wide association study of neutrophil 
levels during clozapine treatment, in 552 individuals with treatment-resistant 
schizophrenia and robustly inferred African genetic ancestry. Two genome-wide 
significant loci were associated with low neutrophil counts during clozapine treatment. 
The most significantly associated locus was driven by rs2814778 (β= -0.9, p=4.21x10-21), a 
known regulatory variant in the Atypical Chemokine Receptor 1 (ACKR1) gene. Individuals 
homozygous for the C allele at rs2814778 were significantly more likely to develop 
neutropenia and have to stop clozapine treatment (OR=20.4, p=3.44x10-7). This genotype, 
also termed ‘Duffy-null’, has previously been shown to be associated with lower 
neutrophil levels in those of African ancestry. Our results indicate the relevance of the 
rs2814778 genotype for those taking clozapine and its potential as a pharmacogenetic 
test, dependent on the outcome of additional safety studies, to assist decision-making in 
the initiation and on-going management of clozapine treatment.  
 
Introduction 
The incidence of psychotic disorders is increased in migrant populations1,2. In particular, 
individuals of African and African-Caribbean ethnicity in the UK and African American 
ethnicity in the US are at especially high risk of developing schizophrenia3,4. The exact 
causes of this are unknown, but are at least in part due to factors associated with being a 
member of a disadvantaged minority, such as socioeconomic stress and isolation5,6. Those 
of African and African-Caribbean ancestry have also been consistently demonstrated to 
have poorer clinical outcomes including higher rates of inpatient admissions involving the 
police or compulsion7,8. Furthermore, a recent study examining cases of first-episode 
psychosis in the UK found that in comparison with White British patients, Black African 
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and Black African-Caribbean patients had a worse long-term clinical course with lower 
rates of recovery8.  
The antipsychotic clozapine is the only licenced treatment for those with schizophrenia 
who fail to respond to other antipsychotics (termed treatment-resistant 
schizophrenia)9,10. While clozapine has been robustly demonstrated to reduce the risk of 
rehospitalisation and to be associated with better symptomatic and functional outcomes 
in treatment-resistant schizophrenia11, it is widely under-prescribed. Clozapine is 
particularly under-utilised in those of African American ethnicity in the US and Black 
African or African-Caribbean ethnicity in the UK12-14, populations that have also been 
consistently associated with a higher rate of clozapine discontinuation15,16. This is at least 
partly due to increased rates of neutropenia in those of African ancestry whilst taking 
clozapine17,18. Neutropenia is defined as an absolute neutrophil count less than 1500 
cells/mm3, while agranulocytosis is diagnosed if the neutrophil count is below 500 
cells/mm3 and is a severe condition that can endanger life. Clozapine treatment increases 
the cumulative risks of neutropenia (3.8%) and agranulocytosis (0.8%), which has led 
many countries to introduce regulatory systems for frequent blood monitoring whilst on 
the medication19. 
Recent evidence has indicated that genetics plays a role in susceptibility to neutropenia 
and agranulocytosis on clozapine. Genetic association studies have implicated HLA-DQB1 
and HLA-B variants in European and Japanese populations20-22, and rs149104283, a SNP 
intronic to transcripts of hepatic transporter genes SLCO1B3 and SLCO1B722 in individuals 
of European ancestry. Reflecting a general dearth of clinical and genetic research in non-
European populations, all studies to date investigating clozapine-associated neutropenia 
have focused predominantly on individuals of European ancestry, limiting the 
generalizability of findings. This is particularly relevant to those of African ancestry who 
are known to have lower baseline neutrophil counts on average compared to those from 
other populations23. In this study, we report the first GWAS of neutrophil levels during 
treatment with clozapine in individuals with treatment-resistant schizophrenia and 
robustly inferred African genetic ancestry.  
 
Methods 
Sample 
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Individuals included in this study were from the CLOZUK2 sample, all of whom were 
prescribed clozapine in the UK with a clinician diagnosis of treatment-resistant 
schizophrenia. The samples were acquired anonymously in partnership with Leyden Delta 
(Nijmegen, Netherlands), a company that supplies and monitors clozapine in the UK, as 
part of the CRESTAR collaborative project (www.crestar-project.eu). The project has 
received UK National Research Ethics Service approval and was in accordance with the UK 
Human Tissue Act. All samples were anonymised and linked with blood monitoring data 
provided from clozapine blood monitoring databases. Full details of the CLOZUK2 sample 
are provided elsewhere24.  
Neutrophil data 
The neutrophil count for each individual was defined as the lowest absolute neutrophil 
count (ANC) on record during clozapine treatment within the blood monitoring database 
held by Leyden Delta, who retain all historical blood results within their monitoring 
system. All individuals were started on clozapine after fulfilling baseline criteria including 
a baseline neutrophil count above 2000 cells/mm3. For clarity, the terms “ANC” and 
“neutrophil count” are used interchangeably. All results of ANC <1500 cells/mm3, 
indicating neutropenia and the standard threshold that triggers discontinuation of 
clozapine in the UK, were confirmed by either a) a consecutive ANC <1500 cells/mm3 or 
b) two or more results of ANC <2000 cells/mm3 before or after the index result. We 
excluded individuals who in the opinion of their treating clinician had an alternative 
explanation for neutropenia such as concomitant immunosuppressive medication (n = 4).  
Genotype quality control and imputation 
The CLOZUK2 sample was genotyped by deCODE Genetics (Reykjavik, Iceland) on the 
Illumina HumanOmniExpress-12 chip. PLINK v1.925 was used for genotype quality control 
following standard protocols26. Maximum per-individual and per-marker missingness 
were set at 2%, and individuals with inbreeding coefficients (F) higher than 0.2 were 
removed from the dataset. After this curation process, 7,287 individuals genotyped at 
698,442 markers remained in the dataset. 
Genotype imputation was performed using the Haplotype Reference Consortium (HRC) 
panel and the pipeline offered by the Michigan Imputation Server27,28. As this pipeline 
allowed for imputation of autosomes only, genotype data from the X-chromosome were 
imputed on the Cardiff University RAVEN cluster29 using the SHAPEIT/IMPUTE2 
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algorithms30 and a combination of the 1000 Genomes phase 3 (1KGPp3) and UK10K 
reference panels31. Both approaches to genotype imputation have been shown to 
produce compatible results and to perform similarly in terms of accuracy for variants with 
minor allele frequencies (MAF) larger than 1%27. After imputation, 20 million SNPs with 
INFO scores higher than 0.8 remained in the dataset. 
Defining Genetic Ancestry 
In order to select a cohort of individuals with African genetic ancestry, we stratified the 
CLOZUK2 individuals using Ancestry Informative Markers (AIMs), routinely employed in 
the field of forensic genetics32. The use of AIMs has been shown to be an efficient way of 
inferring biogeographical ancestry33,34, which reflects the genetic association of an 
individual to a particular continental or sub-continental population group. As these groups 
are broadly defined and show relatively large genetic differentiation35, this approach 
circumvents the problems associated with several other approximations to genetic 
ancestry36, such as self-reported ethnicity37 or country-of-origin38. Our analysis of AIMs in 
the CLOZUK2 identified 566 individuals of Sub-Saharan African ancestry, of whom 552 had 
complete neutrophil count and covariate data, which we term CLOZUK2-AFR. Details on 
the procedure used to select these individuals are provided in Supplementary Methods.  
Post-imputation curation of the CLOZUK-AFR genotype data 
From this sample, a total of 13.5 million SNPs were taken forward for analysis after 
applying a MAF filter of 1% and a Hardy-Weinberg Equilibrium (HWE) filter of p≤1x10-6. 
HWE tests were carried out using the exact “mid-p” test implemented in the 
“HardyWeinberg” R package39, as this test is valid for both autosomal and sex-linked 
markers. Relatedness was assessed using the PC-Relate approach, which identified 18 
pairs of relatives (𝜋𝜋� ≥0.2). For analyses sensitive to confounding by including related 
individuals, such as contingency table tests, we excluded one random member of each of 
these pairs. Otherwise, all individuals were included.  
Association analysis of neutrophil count 
Imputed data from the CLOZUK2-AFR individuals was analysed using the linear mixed 
model (LMM) implemented in GCTA v1.2640, specifically the “leave-one-chromosome-
out” procedure41. Genotype relatedness matrices, needed to control for population 
stratification and family structure in LMM frameworks, were calculated directly from the 
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genotyped SNPs. Covariates used in the analyses included gender, age (at lowest ANC), 
age2 and total days on clozapine treatment. The total number of days on clozapine 
treatment was not associated with neutrophil count. PLINK v1.925 was used to identify 
index SNPs in approximate linkage equilibrium (r2=0.1) using the LD-clumping procedure, 
with a p-value cut-off of 10-4 and a distance cut-off of 3000 kb. Conditional analyses to 
further identify independent index SNPs were carried out using the GCTA-COJO 
procedure42. 
Imputation and analysis of human leukocyte antigen (HLA) alleles 
Previous research into clozapine-associated neutropenia has highlighted polymorphisms 
of the HLA system as drivers of adverse drug reactions in schizophrenia21. In order to 
investigate these, we imputed HLA classical alleles using the software HIBAG v1.1243 (see 
Supplementary Methods for further details). Association testing of the HLA classical 
alleles used linear regression of dosages weighted by imputation probabilities, following 
Levin et al. 201544. Covariates employed matched the GWAS described before, though we 
added the first 5 principal components calculated by PC-AiR45 to correct for potential 
population stratification. 
Code availability 
The code used to run the analysis is available from the authors upon request. 
 
Results 
Absolute neutrophil count in African individuals 
A GWAS of lowest ANC during treatment with clozapine in a total of 552 individuals of 
African ancestry (Figure 1; Supplementary Figure 1, λGC = 0.985) identified six 
independent SNPs (r2<0.1) that were associated at the genome-wide significance level of 
p<5x10-8 (Table 1). Five of those SNPs were in close proximity at a locus (1q23.2) tagging, 
among others, ACKR1, previously called the Duffy Antigen Receptor Complex (DARC). The 
most significantly associated SNP in that locus was rs2814778 (β=-0.86, P=4.21x10-21), 
which is a regulatory variant in the ACKR1 promoter region. None of the other SNPs 
remained genome-wide significant after a mixed model analysis conditional on 
rs2814778, indicating this SNP is responsible for the association signal of the entire locus 
(Supplementary Figure 2). The other genome-wide significant signal was rs77198048 
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(β=0.34, P=8.95x10-9) an intronic variant (MAF=1.07%) of the Zinc Finger Protein 618 
(ZNF618) gene on chromosome 9 (9q32). Our sample size had 80% power to detect a 
β≥1.06 for alleles with MAF≥0.05 at the genome-wide significance level of P<5x10-8, and 
98% power to detect the association of a variant with similar MAF and effect size to 
rs2814778. 
rs2814778 genotype effect on neutrophil counts 
We examined the effects of the different rs2814778 genotypes on ANC after excluding 18 
related individuals who were included in the mixed model analysis, leaving 534 CLOZUK2-
AFR in the sample. Of these, 419 individuals were homozygous for the C (African) allele, 
106 were heterozygous and 9 homozygous for the T (European) allele. A Mann-Whitney 
test (P=0.099) did not show significant ANC differences between CT and TT individuals, 
supporting previous evidence that the C allele has a recessive effect on neutrophil 
counts46. Thus, for all further analyses we combined individuals with TC and TT genotypes. 
Figure 2A displays the distribution of neutrophil counts during treatment with clozapine 
by rs2814778 genotype in our African ancestry sample. Individuals with the CC genotype 
had a median lowest ANC of 1900/mm3 compared to 2900/mm3 for CT/TT individuals 
(P=3.55x10-24).  
Figure 2B is a density plot showing the ANC distribution in different CLOZUK2 ancestry 
subsets (Supplementary Methods; Supplementary Table 5), stratified by rs2814778 
genotype. While the difference between CC and CT/TT individuals is clearly shown, the CC 
neutrophil distributions are similar among Sub-Saharan Africans and North Africans 
(Kolmogorov-Smirnov test P=0.941). Similarly, the neutrophil distributions of CT/TT 
groups show no difference between Sub-Saharan Africans and all other ancestries 
(Kolmogorov-Smirnov test P=0.234, see Figure 2B).  
Given these results we then tested explicitly whether the rs2814778 Duffy-null genotype 
is more informative of ANC than genetic ancestry, using generalised linear modelling 
(Supplementary Methods). A model including genetic ancestry (European or African) and 
the GWAS covariates explained 8.29% of the variance in ANC. When the rs2814778 
genotype was added to this model, the variance explained increased to 10.94%, and 
genetic ancestry was no longer associated with ANC. The removal of genetic ancestry 
resulted in a statistically equivalent model (likelihood ratio test P=0.794) indicating that 
the rs2814778 genotype is more informative of ANC than genetic ancestry. Adding the 
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second GWS SNP (rs77198048) to this model also resulted in a statistically equivalent 
model (likelihood ratio test P=0.182). Analogous results were obtained by fitting these 
models to predict neutropenia (ANC < 1500 cells/mm3) in our sample, which yielded a 
maximum explained variance of 13.03%. 
A total of 83 (19.81%) CC individuals had neutropenia during treatment with clozapine 
(ANC < 1500/mm3) in comparison to 2 (1.74%) individuals with a T allele (Table 2). In both 
the US and UK, thresholds of ANC below which alterations in clozapine monitoring and 
management are indicated, have been defined based on normative values from European 
populations. In the UK, ANC results below 2000/mm3 mandate closer monitoring and 
more regular blood testing whereas ANC < 1500/mm3 requires clozapine treatment to be 
withdrawn. All study individuals who developed neutropenia had clozapine immediately 
discontinued, although some were later rechallenged. We used Barnard’s exact test to 
estimate the effect size of rs2814778 on crossing these thresholds, given their important 
clinical implications. CC individuals are much more likely to develop an ANC < 2000/mm3 
(OR=6.84, 95% CI=4.13-13.67, P=2.90x10-16), and an ANC < 1500/mm3 (OR=20.36, 95% 
CI=5.37-314.28, P=3.44x10-7) than T allele carriers. We could not test genotype-mediated 
differences at lower ANC thresholds, due to the absence of CT/TT carriers.  
rs2814778 and benign ethnic neutropenia 
There are regulatory mechanisms in place in the US and UK to lower the neutropenia 
threshold at which clozapine has to be discontinued for those deemed to have benign 
ethnic neutropenia (BEN), a hereditary condition characterised by mild, chronic 
neutropenia47-50. Of the 74 individuals in our sample with a formal diagnosis of BEN 
provided by a Consultant Haematologist, 72 (97.30%) have the CC genotype for rs2814778 
(Table 2). Considering the safety and clinical outcomes of the 83 individuals with a CC 
genotype and ANC < 1500 cells/mm3, a total of 80 were rechallenged with clozapine. Of 
these, at the time of data collection 75 (93.75%) were still maintained on treatment, 4 
(5.0%) had subsequently discontinued, and 1 had died (1.25%, unrelated to ANC). It is not 
valid to test the sensitivity and specificity of rs2814778 as a predictive test for BEN in this 
sample due to the lack of systematic screening for BEN.  
Association of rs77198048  
The second genome-wide significant polymorphism was rs77198048 on chromosome 9 
(Table 1). This signal comes from a single intronic SNP with no known function and there 
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were no other SNPs in LD (r2>0.6) from this region in our sample (or on the 1000 genomes 
African reference genomes). However, we were not able to identify any reasons related 
to population stratification or admixture (Supplementary Figure 3), which would suggest 
that this finding is an artefact. None of the 10 individuals that had the minor T allele had 
neutropenia (ANC < 1500 cells/mm3), and thus we could not reliably statistically test the 
impact on neutropenia case/control status. 
Association analysis of HLA alleles 
Using the HIBAG pipeline, we were able to impute 11 HLA-DQB1 classical alleles and 21 
HLA-B classical alleles at MAF > 1% in the CLOZUK2-AFR sample; none were significantly 
associated with ANC after Bonferroni correction for multiple testing (P<0.05/32=1.56x10-
3), although the HLA-B*45:01 allele was nominally significant (P=4.45x10-3).  
Assessment of previous findings from European populations 
We were unable to impute any of the following variants implicated in recent association 
studies of clozapine-associated neutropenia in European populations due to the risk 
alleles being absent or very rare in CLOZUK2-AFR; rs149104283 (intronic to transcripts of 
SLCO1B3 and SLCO1B7)22, the HLA-DQB1 candidate SNP rs11333249422, or the HLA-DQB1 
(126Q) and HLA-B (158T) amino acid polymorphisms21.  
 
Discussion 
In the first genetic association study of neutrophil counts during clozapine treatment in 
individuals of African ancestry, we identify two genome-wide significant loci. The most 
significant association is attributable to rs2814778 (P = 4.21x10-21), a regulatory variant in 
ACKR1 which has previously been associated with lower neutrophil counts in individuals 
of African ancestry, and is thought to be causal for BEN. We demonstrate that in those 
taking clozapine, individuals homozygous for the C allele for rs2814778, also known as the 
Duffy-null genotype, are substantially more likely (OR=20.36) to be classified as having 
neutropenia (ANC < 1500 cells/mm3), the threshold at which clozapine must be stopped. 
Our results indicate the relevance of the rs2814778 genotype for those taking clozapine 
and its potential as a pharmacogenetic test, dependent on the outcome of additional 
safety studies, to assist decision-making in the initiation and on-going management of 
clozapine treatment. 
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The rs2814778 Duffy-null genotype had a frequency of 78% in our study population of UK 
people with African ancestry and has an ~65% frequency in African Americans51 
(Supplementary Table 6). In those of African ancestry, it has been robustly implicated in 
white blood cell and neutrophil counts in several large meta-analyses46,51-53. It is also 
considered to be the cause of BEN48, an hereditary condition characterized by low 
neutrophil counts which occurs in 25-50% of individuals with African or Middle Eastern 
ancestry47-50. In support of rs2814778 as causal for BEN, over 97% of individuals diagnosed 
with BEN in our study were homozygous for the C allele. For those on clozapine, we show 
that rs2814778 genotype is a better predictor of low ANC than ancestry. Furthermore, the 
distribution of neutrophil counts closely followed genotype at rs2814778 regardless of 
ancestry (African, European and South-West Asian) (Figure 2B). Given that rs2814778 is 
the likely cause of BEN, this study implies that BEN is not adequately diagnosed in 
individuals treated with clozapine. Indeed this is demonstrated by our finding that only 
59% of those with the CC genotype and an ANC between 1000 and 1500 cells/mm3 had a 
clinical BEN diagnosis. Indirect evidence also supports the hypothesis that BEN is under-
diagnosed; BEN had a much lower frequency (14%) in our sample than expected from its 
prevalence of 25-50% in healthy populations of African ancestry47-50. Furthermore, the 
rates of BEN diagnosis in this sample will be overestimated given its cross-sectional nature 
(at the point of sample collection), which enriches for those that have been re-challenged 
with clozapine. Others have similarly noted under-representation of BEN in smaller 
samples of people of African ancestry taking clozapine14.  
The Duffy-null rs2814778 (C) allele disrupts an erythroid transcription factor GATA-1 
binding site in the promoter of ACKR1 and as a result, the erythrocytes of homozygote 
rs2814778 carriers do not express ACKR1 protein54. Erythrocytes lacking this Duffy antigen 
are refractory to the malaria parasite Plasmodium vivax infection and hence the Duffy-
null variant confers an evolutionary advantage55. Recent experimental work in mice has 
shown that ACKR1 deficiencies during early haematopoiesis do not result in reduced 
production of neutrophils, rather neutrophils exhibit altered phenotypic characteristics 
that result in their preferential loss from blood by egress into tissues, particularly via 
migration to the spleen, thus causing neutropenia56,57. Importantly there is good evidence 
that BEN does not lead to increased rates of infection or clozapine-associated 
agranulocytosis17,18,58. In light of this, for patients with a diagnosis of BEN, clozapine 
monitoring thresholds in the UK are reduced to ANC > 1500 cells/mm3 and ANC < 1000 
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cells/mm3 for initiation and discontinuation, respectively. The recently implemented 
Clozapine Risk Evaluation and Mitigation Strategy (REMS) program in the US also allocates 
BEN patients separate monitoring thresholds of ANC > 1000 cells/mm3 for initiation and 
ANC < 500 cells/mm3 for discontinuation.  
Our study supports the safety of separate thresholds for those with BEN; 94% of 
rs2814778 C homozygotes with ANC < 1500 cells/mm3 were successfully maintained on 
clozapine treatment after reinstatement. However, in clinical practice, the process of 
diagnosing BEN is challenging, particularly for those who may be acutely psychotic at the 
point of clozapine initiation or as a result of clozapine withdrawal. In the UK and the US, 
a BEN diagnosis is made by a specialist in haematology after assessing the individual’s 
ancestral background, drug history, and the presence of stable low neutrophil counts in 
the absence of infection. All this necessitates referral by psychiatrists, attendance at 
haematology outpatient clinics, further blood sampling and review. In light of these 
practical considerations, it is perhaps unsurprising that only a minority of those who have 
treatment-resistant schizophrenia and who are eligible for a BEN diagnosis actually 
receive it, and then go on to have appropriate management with clozapine14.  
Our results indicate that genotyping rs2814778 may offer a simple but sensitive 
alternative strategy for the diagnosis of BEN. In the context of clozapine treatment, 
individuals who are homozygous for the C allele and who do not show signs of 
compromised immune function could have revised neutrophil thresholds in line with 
current BEN monitoring procedures. This ability to prospectively lower acceptable 
neutrophil thresholds could address the underutilisation of clozapine in those of African 
ancestry by (i) enabling more of those suitable for clozapine to start the medication given 
a lower baseline threshold (ii) avoiding disruption of treatment for those who discontinue 
clozapine and may or may not under current arrangements be subsequently diagnosed 
with BEN. In addition to identifying BEN, rs2814778 could also avoid misclassification; the 
two individuals that had a BEN diagnosis but did not have the Duffy-null genotype in this 
study have likely been diagnosed incorrectly and could therefore be at increased risk of 
agranulocytosis. It is not known how many people are denied clozapine due to neutrophil 
levels that fall below the permitted threshold for initiation (ANC > 2000 cells/mm3), 
however we do know that a pre-treatment analysis of neutrophil levels would not have 
identified the individuals in this study who would have benefitted from such a test. 
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Furthermore, the potential applications could extend beyond those of African ancestry 
given rs2814778 occurs at non trivial rates in other populations in which malaria has been 
historically endemic, including some parts of the Middle East, South West Asia and 
Oceania (Supplementary Table 6)59.  
Further studies are required prior to the implementation of Duffy-null genotype testing 
to confirm its safety and utility both in prospectively determining BEN status and also to 
investigate the risk of agranulocytosis when re-challenging Duffy-null patients, though it 
is reassuring that our cross-sectional data and other currently available evidence 
support the safety of such approaches17,18,58. We envisage that the genetic test could be 
conducted by clinical or commercial laboratories with DNA sampling being added to the 
current pre-treatment screening procedures for clozapine, which includes blood testing, 
once regulatory approval is in place. Recent studies suggest that current genotyping 
procedures for determining Duffy-null status are both robust and reproducible, and thus 
their implementation in the context of a clinical blood monitoring service should be 
straightforward60,61.  
It is important to note that the Duffy-null genotype is the main causal factor for the Duffy-
null phenotype (classically termed “Fy(a-b-)”)59,62. Recent studies have shown that direct 
genotyping is the best available method to identify Duffy-null individuals in the context of 
neutropenia60,61, since in the isolated handful of reported cases with Duffy-null phenotype 
in the absence of the rs2814778 mutation, neutropenia is not observed63. A further 
challenge to using Duffy-null phenotyping arises from other ACKR1 mutations causing 
weak antigen expression which can mimic the Duffy-null phenotype causing serological 
ambiguity, resulting in misclassification of up to 3.5% of individuals depending on 
population60,62,64. For this reason, we argue that genotyping of rs2814778 would 
outperform the serological typing of the Duffy-null phenotype. 
The second genome-wide significant finding corresponds to an intronic variant in the 
ZNF618 gene, which has been characterised as a contributor to methylation and 
chromatin binding of epigenetic regulators65. Given this association comes from a single 
SNP rs77198048 with no known function, we interpret this finding with caution. 
Nonetheless we were not able to identify any reasons to suggest that this finding is an 
artefact but would strongly suggest Independent replication is required to confirm this 
result.  
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The Duffy-null association we report in this study adds to existing evidence from our group 
and others, which together indicate three potential pathways to clozapine-associated 
neutropenia; (i) immune-mediated20-22, (ii) hepatic transport and potentially drug 
toxicity22, and (iii) genetic factors that cause benign neutropenia causally unrelated to 
clozapine. In summary, we provide novel insights into the genetic architecture of 
neutrophil counts during clozapine treatment in individuals with African genetic ancestry. 
In the first genome-wide association study of neutrophil levels during clozapine 
treatment, we demonstrate strong association with rs2814778, a regulatory variant in the 
ACKR1 gene that has also been described as the genetic basis for BEN. We suggest that 
rs2814778 genotyping offers an opportunity for personalised medicine in psychiatry 
although crucially we recognise that further research is needed to establish the safety, 
acceptability, uptake, clinical utility, and the practical outcomes and cost-benefits of such 
a test.  
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Figure 1 
Manhattan plot of the lowest ANC GWAS in the CLOZUK2-AFR sample. The genome-
wide significant peak at chromosome 1 corresponds to the ACKR1 locus mentioned in 
the text. 
 
Figure 2 
A: Histogram of lowest neutrophil count in the CLOZUK2-AFR sample, stratified by 
rs2814778 genotype. B: Scaled density plots of ANC in the different CLOZUK2 
biogeographical ancestry subsets, stratified by rs2814778 genotype. 
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Table 1 
 
SNP CHR BP A1 A1 Frequency Beta SE P-value 
rs2814778 1 159174683 C 88.38% -0.856 0.091 4.21 x10-21 
rs4971072 1 155273869 G 92.25% -0.700 0.106 3.61 x10-11 
rs260913 1 163968414 C 4.45% 0.788 0.131 1.89 x10-9 
rs12128479 1 162268123 G 1.63% 1.205 0.203 2.98 x10-9 
rs77198048 9 116789254 T 1.07% 1.625 0.282 8.95 x10-9 
rs12143237 1 162480145 A 2.90% 0.877 0.153 1.11 x10-8 
 
Genome-wide significant SNPs from the ANC GWAS in the CLOZUK2-AFR sample. 
Columns represent; variant name (SNP), chromosome (CHR), base position (BP), risk 
allele (A1), frequency of the risk allele (A1 Frequency), beta (Beta), standard error (SE) 
and association P-value.  
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Table 2  
 
 CC  TC/TT 
 
N (% total CC) N BEN (%)  
N (% total 
TC/TT) N BEN (%) 
ANC < 500 1 (0.24%) 1 (100.00%)  0 (0.00%) - 
500 ≥ ANC < 1000 19 (4.53%) 14 (73.68%)  0 (0.00%) - 
1000 ≥ ANC < 
1500 63 (15.04%) 
37 
(58.73%)  2 (1.74%) 
1 
(50.00%) 
1500 ≥ ANC < 
2000 149 (35.56%) 
17 
(11.40%)  16 (13.91%) 0 (0.00%) 
ANC ≥ 2000  187 (44.63%) 3 (1.60%)  97 (84.35%) 1 (1.03%) 
Total 419 (100.00%) 
72 
(17.18%)  115 (100.00%) 2 (1.73%) 
 
ANC and BEN diagnosis in CLOZUK2-AFR, stratified by rs2814778 genotype.  
The individual with an ANC < 500 cells/mm3 had an ANC of 400 cells/mm3 15 weeks after 
onset of clozapine treatment. They were rechallenged three days after discontinuing 
clozapine and although did not have any further agranulocytosis results, they did 
develop additional amber (ANC < 1500 cells/mm3) results. The patient was still being 
successfully maintained on clozapine treatment when the data was extracted. 
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Biogeographical ancestry inference 
Identification of a subset of ancestry-informative markers (AIMs) 
Given the disparity of existing forensic AIM panels1 and their modest coverage of SNPs present in 
Illumina genotyping chips2, we developed our own set of AIMs using publicly available genotype data. 
To maximise the range of ancestries that a sample could be assigned to, we first obtained the data 
from the Human Genome Diversity Project (HGDP) sample genotyped by Li et al. 20083, which contains 
52 worldwide populations, each represented by 5-46 individuals (see Supplementary Table 1 of 
Leutenegger et al. 20114 for full details). We excluded the 10 individuals with Uyghur ethnicity from 
our analyses, as this population is at the geographic border between South East and South West Asia, 
and shows heavy admixture from both regions5. Genotype data of the remaining 930 samples was 
merged and restricted to SNPs in common with the CLOZUK2 sample, which left 349,242 SNPs 
available for analysis in the HGDP individuals. 
To define the AIMs we used the FST-based procedure of Kersbergen et al. 20096, which requires 
defining the desired ancestry groups a priori. Thus, we divided the HGDP sample in the 
biogeographical categories used by Li et al. 20083 (Supplementary Table 1), and calculated pairwise 
between-group FST metrics for each SNP using PLINK v1.9. Given that the CLOZUK2 sample was 
recruited in the UK, and most of the individuals within it are expected to have European ancestry7, we 
retained only the 6 pairwise comparisons that involved European populations. Then, for each of these, 
we selected all the SNPs in the top 2.5 percentile of the FST values3, assuming that this metric follows 
a beta distribution8. The resulting SNPs were then pruned (r2=0.4) using the linkage disequilibrium (LD) 
structure of their corresponding non-European population (i.e. the SNPs selected from the Europe-
Africa pairwise comparison were LD-pruned using the African samples as reference). This resulted in 
16,114 LD-independent SNPs, which were included in the AIM panel. We note that this number is 
much larger than the SNP sets used in routine forensic practice, and could potentially be reduced 
further by applying more stringent marker selection criteria2. However, we consider this panel to be 
suitable for our purposes, as these involve inferring the ancestry of samples that have already been 
genotyped, rather than efficiently genotyping samples de novo. 
Building a classification model for biogeographical ancestry 
In order to automate the ancestry inference, we trained a simple machine learning model using linear 
discriminant analysis (LDA), which has been used successfully in similar scenarios9,10. In order to reduce 
the AIMs to a small set of independent variables we used the principal component analysis (PCA) 
implemented in EIGENSTRAT v6.1211 on the HGDP AIM SNPs. Then, to retain a number of principal 
components proportional to the level of population structure in the sample, we used a Tracy-Widom 
test12. The first 32 PCs were nominally significant in this analysis, and were used to train the LDA 
model. By using 10-fold cross-validation we determined that LDA could retrieve the original ancestries 
of each HGDP sample with an accuracy of up to 99.74%. 
Validation on an independent sample of known ancestry 
For validation purposes we retrieved the data from the Affymetrix Human Origins (AHO) project, 
described in Lazaridis et al. 201413. This is a collection of samples from 200 worldwide populations, 
with an emphasis on small and indigenous ethnic groups. From the publicly available genotype data 
we excluded 841 HGDP individuals that had been also genotyped in this project. Also, given that the 
Indian subcontinent was only sparsely covered, we added the genotypes of 168 Indians from the South 
Asian Genome Project (SAGP) sample genotyped by Chambers et al. 201414. This left a total of 1,276 
individuals in AHO+SAGP, which were merged with the 16,114 HGDP AIMs. In order to take full 
advantage of the AIM panel, we did not restrict the merged dataset to overlapping SNPs, leaving those 
AIMs not present in AHO+SAGP as missing values. Afterwards we ran the EIGENSTRAT PCA algorithm 
on the “projection” mode, with the HGDP samples as references. This mode runs PCA on the reference 
data only, using afterwards a least-squares method to infer the coordinates in each PC of all the other 
samples, considering the non-missing SNP data15. The resulting PCA coordinates are effectively 
unbiased by the AHO+SAGP genotypes, and thus are valid to run the classification model trained 
before. Based on the first 32 PCs, LDA correctly classified 75.69% to 100% of the AHO+SAGP samples, 
depending on the ancestry (Supplementary Table 2). In fact, as the AHO samples included some 
biogeographical ancestries not properly represented in the HGDP categories (such as “Central Asian” 
or “North African”) we noted that our algorithm classified them in those ancestries that were 
genetically more similar (see Extended Data Figure 3 of Lazaridis et al. 201413). Though we regard this 
performance as good for our purposes, this is conservative as a validation approach, as only 4,200 of 
the AHO+SAGP SNPs overlapped with our AIM panel. Such modest concordance is due to AHO and 
HGDP having been genotyped on different array platforms. 
Inferring biogeographical ancestry in CLOZUK2 
In order to classify the CLOZUK2 individuals we merged the CLOZUK2 genotype data with the 16,114 
HGDP AIMs, and repeated the generation of PCs using the EIGENSTRAT “projection” mode, as 
described above. As in a sample of this characteristics we expect admixed people to be present, we 
extracted individual classification probabilities from the LDA model, and retained only individuals that 
achieved a classification probability for a single biogeographical ancestry of 90% or more 
(Supplementary Table 3). 
Independence with the CLOZUK1 sample used in previous studies 
To ensure independence with our previous report of genetic variants involved in clozapine-associated 
neutropenia16, genetic relatedness was estimated with the individuals of the CLOZUK1 dataset, 
included in said study. For this, the CLOZUK2-AFR and CLOZUK1 genotypes were merged, and 
relatedness estimated using PC-Relate17, controlling for the first 5 ancestry-specific principal 
components calculated by PC-AiR18. This approach been found to result in reliable calculations of 
kinship coefficients (𝜋𝜋�), even in the presence of strong population structure17. As expected, given that 
the Legge et al. 2016 study16 was focused on a European population sample, no duplicates or close 
relatives (𝜋𝜋� ≥ 0.2) were found. 
Imputation of Human Leukocyte Antigen (HLA) classical alleles 
Due to the complex LD structure of this area of the genome, specialised protocols are necessary to 
impute HLA alleles. While the SNP2HLA method has been used in previous research on European 
populations19, it lacks the necessary reference data to be used in a Sub-Saharan African sample. Thus, 
we used the machine learning approach implemented in HIBAG v1.1220, which can impute 4-digit 
classical HLA alleles from genotype data. For this we used the provided HLARES African reference 
sample21, and retained only the alleles that passed a MAF threshold of 1%. Allele frequencies were 
also cross-checked with those recently published from the Kenyan Luo population22, and no 
discrepancies larger than 5% were found (Supplementary Table 4).  
Statistical modelling of neutrophil counts 
In order to estimate the relative importance of variables defined as predictors of ANC, we fitted 
generalised linear models using the “gamlss” R package23. A log-normal distribution was assumed for 
the ANC outcome24, and the covariates used in the GWAS were used to define a baseline model. This 
model was extended by adding two binary covariates representative of genetic ancestry: “European” 
and “African” (which included “Sub-Saharan African” and “Middle Eastern / North African”). Finally, 
one covariate representative of the genome-wide significant finding from the GWAS (rs2814778) was 
also added to define a full model. Variances explained by these models were calculated with the 
Nagelkerke’s pseudo-R2 formula. Given that all the models we defined were nested, goodness-of-fit 
was assessed using likelihood ratio tests.  
Supplementary Table 1 
Individuals in the HGDP data used to train our ancestry classification model. We note the “South West 
Asian” category was called “Central/South Asia” in Li et al. 2008. We have renamed it to more properly 
reflect its geographical provenance, as all of its samples were recruited in Pakistan. 
Biogeographical ancestry category N 
Sub-Saharan African 101 
Middle Eastern 163 
European 157 
South West Asian 190 
South East Asian 228 
Oceanian 27 
American 64 
 
Supplementary Table 2 
Classification accuracy of our LDA model in the AHO+SAGP dataset. “Accuracy” indicates the proportion of AHO+SAGP samples that were correctly classified 
in a given category. Note that, as expected, misclassifications between ancestries are proportional to their genetic similarity13. 
 
Inferred ancestry 
Original ancestry Sub-Saharan African Middle Eastern European South West Asian South East Asian Oceanian American 
Sub-Saharan African 124 19 0 0 0 0 0 
North African 0 42 1 0 0 0 0 
Middle Eastern 0 109 27 8 0 0 0 
European 0 40 332 11 0 0 0 
Central Asian 0 0 9 57 174 0 0 
South West Asian 0 1 0 210 9 0 0 
South East Asian 0 0 0 0 46 0 0 
Oceanian 0 0 0 0 0 3 0 
American 11* 0 1* 0 0 0 42 
ACCURACY 86.71% 75.69% 86.68% 95.46% 100.00% 100.00% 77.78% 
 
* These samples were recruited in the United States of America, and thus it is possible that they bear substantial admixture from outside that continent.
Supplementary Table 3 
Ancestry classification of the Individuals in the CLOZUK2 sample. Given the results of the LDA model 
validation (see text), the “Middle Eastern” category was recognised to encompass individuals from the 
North African biogeographical region. Individuals in the “admixed” category did not achieve 90% 
classification probability for any of the other categories. 
Biogeographical ancestry category N 
Sub-Saharan African 566 
Middle Eastern / North African 204 
European 5900 
South West Asian 351 
South East Asian 58 
Oceanian 0 
American 0 
Admixed 208 
 
  
Supplementary Table 4 
HLA 4-digit allele frequencies in the CLOZUK2-AFR sample and in the Luo population from Kenya, 
assessed by Arlehamn et al. 201722. Only alleles with a frequency greater than 1% in CLOZUK2-AFR 
are shown. 
  HLA 4-digit allele Allele frequency in CLOZUK2-AFR 
Allele frequency 
in Luo 
B*07:02 8.11% 3.50% 
B*08:01 1.22% 3.50% 
B*14:01 1.00% N/A 
B*14:02 1.56% 3.00% 
B*15:03 7.22% 6.00% 
B*15:10 6.67% 4.50% 
B*15:16 1.89% 0.50% 
B*18:01 2.78% 3.50% 
B*35:01 7.22% 3.00% 
B*39:10 1.67% N/A 
B*42:01 7.22% 11.50% 
B*44:03 6.22% 2.50% 
B*45:01 4.00% 8.00% 
B*49:01 2.56% 1.00% 
B*51:01 1.78% 3.00% 
B*52:01 4.67% N/A 
B*53:01 14.56% 10.00% 
B*57:02 1.22% 1.50% 
B*57:03 3.67% 2.00% 
B*58:01 4.11% 7.50% 
B*58:02 4.56% 8.50% 
DQB1*02:01 10.67% 10.50% 
DQB1*02:02 9.83% 7.50% 
DQB1*03:01 15.91% 20.00% 
DQB1*03:02 3.09% 1.00% 
DQB1*03:19 3.55% N/A 
DQB1*04:02 6.44% 11.00% 
DQB1*05:01 16.10% 17.00% 
DQB1*05:02 2.80% 0.50% 
DQB1*06:02 25.37% 22.50% 
DQB1*06:03 2.99% 2.00% 
DQB1*06:09 1.03% 5.50% 
Supplementary Table 5 
ANC in the different CLOZUK2 biogeographical ancestry subsets (AFR = Sub-Saharan African, MES = 
Middle Eastern / North African, EUR= European, SAS = South West Asian), stratified by genotype. Note 
that a random member of each pair of genetically related individuals (𝜋𝜋� ≥ 0.2) inside each population 
has been excluded from these counts. 
 CC  TC/TT 
 AFR MES  AFR MES EUR SAS 
ANC < 0.5 1  
(0.24%) 
0 
(0.00%) 
 0 
(0.00%) 
0 
(0.00%) 
7 
(0.12%) 
0 
(0.00%) 
0.5 ≥ ANC < 1 19 
(4.53%) 
0 
(0.00%) 
 0 
(0.00%) 
0 
(0.00%) 
18 
(0.31%) 
1 
(0.30%) 
1 ≥ ANC < 1.5 63 
(15.04%) 
10 
(25.00%) 
 2 
(1.74%) 
3 
(1.90%) 
96 
(1.68%) 
7 
(2.08%) 
1.5 ≥ ANC < 2 149 
(35.56%) 
13 
(32.50%) 
 16 
(13.91%) 
22 
(13.92%) 
744 
(13.02%) 
54 
(16.07%) 
ANC ≥ 2 187 
(44.63%) 
17 
(42.50%) 
 97 
(84.35%) 
133 
(84.18%) 
4851 
(84.87%) 
274 
(81.55%) 
Total 419 
(100.00%) 
40 
(100.00%) 
 115 
(100.00%) 
158 
(100.00%) 
5716 
(100.00) 
336 
(100.00%) 
 
  
Supplementary Table 6 
Frequency of rs2814778 in human populations with a C allele frequency greater than 0.05 indicating 
polygenicity, taken from The Allele Frequency Database (ALFRED, http://alfred.med.yale.edu, update 
23/01/2018)25. ALFRED is a free, web accessible, expert-curated compilation of allele frequency data 
on DNA sequence polymorphisms in anthropologically defined human populations.  
Geographic region Population Sample Size C allele freq T allele freq 
Africa Algerian 70 0.214 0.786 
Africa Bantu speakers 40 0.952 0.048 
Africa Berber 60 0.217 0.783 
Africa Biaka 208 0.995 0.005 
Africa Chagga 88 0.989 0.011 
Africa Esan 198 1 0 
Africa Ethiopian Jews 116 0.821 0.179 
Africa Ghanaian 70 0.986 0.014 
Africa Hausa 126 1.000 0.000 
Africa Ibo 94 1 0 
Africa Ivoirian 66 0.985 0.015 
Africa Libya 258 0.182 0.818 
Africa Lisongo 14 1 0 
Africa Luhya 706 0.994 0.006 
Africa Malinke 226 1 0 
Africa Masai 324 0.935 0.065 
Africa Mbuti 104 0.981 0.019 
Africa Mende 170 1 0 
Africa Moroccans 178 0.175 0.825 
Africa Mozabite 112 0.214 0.786 
Africa San 14 1 0 
Africa Sandawe 78 0.974 0.026 
Africa Sierra Leone 90 1 0 
Africa Somali 108 0.861 0.139 
Africa Tunisian 766 0.206 0.794 
Africa Yoruba 750 0.997 0.003 
Africa Zaramo 78 1 0 
Asia Arabs (U.A.E.) 138 0.424 0.576 
Asia Balochi 100 0.180 0.820 
Asia Bedouin 98 0.35 0.65 
Asia Brahui 50 0.06 0.94 
Asia Druze 202 0.064 0.936 
Asia Kachari 30 0.067 0.933 
Asia Kuwaiti 26 0.308 0.692 
Asia Makrani 32 0.312 0.688 
Asia Palestinian 228 0.327 0.673 
Asia Saudi 196 0.648 0.352 
Asia Timorese 234 0.089 0.911 
Asia Yemenite Jews 130 0.507 0.493 
Europe Cypriot 118 0.068 0.932 
Europe Sephardic Jews 52 0.231 0.769 
Europe Spanish (Andalusian) 126 0.278 0.722 
North America African Americans 692 0.826 0.174 
North America Afro-Caribbeans 192 0.885 0.115 
North America Afro-Ecuadorian 58 0.672 0.328 
North America Colombian 318 0.074 0.926 
North America Guihiba 20 0.05 0.95 
North America Jamaican 90 0.856 0.144 
North America Puerto Rican 318 0.129 0.871 
Oceania Papuan New Guinean 42 0.071 0.929 
Oceania Samoans 16 0.125 0.875 
  
Supplementary Figure 1 
 
QQ plot (λGC = 0.985) of the lowest ANC GWAS in CLOZUK2-AFR. 
  
Supplementary Figure 2 
 
Detail of the 1q23.2 region, showing the raw ANC GWAS p-values before (upper plot, red) after (lower 
plot, blue) conditioning on rs2814778 genotype counts. The ACKR1 gene is highlighted in red. 
  
Supplementary Figure 3 
 
High-resolution local admixture plot of a segment of chromosome 9 produced by the ELAI software26, 
showing ten individuals that are T/A heterozygotes for the rs77198048 SNP. Proportions of European 
(blue) and African (red) ancestry were inferred using 1000 Genomes EUR/AFR superpopulation 
genotype data, and 10 ELAI runs over a 5 Mb region (chr9:114000000-119000000). Prior admixture 
date between EUR/AFR was set to 80 generations27. No introgressed European haplotype can be 
consistently detected around the 116.78 mb mark, which harbours our variant of interest. Note that 
while some of the individuals might bear a certain degree of European admixture, this extends to 
segments much larger than the average African LD block28 (153kb), and thus should be properly 
accounted by the mixed-model association procedure29.   
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